Drug Profile

CG 0161

Alternative Names: CG0161

Latest Information Update: 28 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Unknown
Developer CG Oncolgy
Class Antibodies; Antineoplastics; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Sep 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
25 Mar 2020 Cold Genesys is now called CG Oncology
22 Aug 2019 Preclinical trials in Cancer in USA (Parenteral), prior to August 2019 (Cold Genesys pipeline, August 2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com